Zimmer Partners’s Neumora Therapeutics NMRA Stock Holding History

Zimmer Partners’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-12,500	Closed	-$176K	–	132
2023 Q3	$176K	Buy	+12,500	New	+$156K	﹤0.01%	121

Other funds holding NMRA

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Zimmer Partners's NMRA Position: Q4 2023 in Review

Zimmer Partners sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 12,500 shares — an estimated $176K sold.

Zimmer Partners first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $176K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

Zimmer Partners reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
Zimmer Partners sold 12,500 Neumora Therapeutics shares in Q4 2023, an estimated $176K.
Zimmer Partners first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
Zimmer Partners's Neumora Therapeutics position peaked at $176K in Q3 2023.
60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on Zimmer Partners's 13F filing for Q4 2023, filed 14 Feb 2024.